Single-cell and bulk RNA sequencing reveal cancer-associated fibroblast heterogeneity and a prognostic signature in prostate cancer

被引:6
|
作者
Liu, Wen [1 ,2 ]
Wang, Miaomiao [1 ,2 ]
Wang, Miao [1 ]
Liu, Ming [1 ,2 ]
机构
[1] Chinese Acad Med Sci, Beijing Hosp, Inst Geriatr Med, Natl Ctr Gerontol,Dept Urol, 1 DaHua Rd, Beijing 100730, Peoples R China
[2] Chinese Acad Med Sci, Peking Union Med Coll, Grad Sch, Beijing, Peoples R China
关键词
cancer-associated fibroblast; prognostic signature; prostate cancer; single-cell; MACROPHAGES; PROGRESSION; INFERENCE;
D O I
10.1097/MD.0000000000034611
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cancer-associated fibroblasts (CAFs), the central players in the tumor microenvironment (TME), can promote tumor progression and metastasis via various functions. However, the properties of CAFs in prostate cancer (PCa) have not been fully assessed. Therefore, we aimed to examine the CAF characteristics in PCa and construct a CAF-derived signature to predict PCa prognosis. CAFs were identified using single-cell RNA sequencing (scRNA-seq) data from 3 studies. We performed the FindAllMarkers function to extract CAF marker genes and constructed a signature to predict the biochemical relapse-free survival (bRFS) of PCa in the Cancer Genome Atlas (TCGA) cohort. Subsequently, different algorithms were applied to reveal the differences of the TME, immune infiltration, treatment responses in the high- and low-risk groups. Additionally, the CAF heterogeneity was assessed in PCa, which were confirmed by the functional enrichment analysis, gene set enrichment analysis (GSEA), and AUCell method. The scRNA-seq analysis identified a CAF cluster with 783 cells and determined 183 CAF marker genes. Cell-cell communication revealed extensive interactions between fibroblasts and immune cells. A CAF-related prognostic model, containing 7 genes (ASPN, AEBP1, ALDH1A1, BGN, COL1A1, PAGE4 and RASD1), was developed to predict bRFS and validated by 4 independent bulk RNA-seq cohorts. Moreover, the high-risk group of the signature score connected with an immunosuppressive TME, such as a higher level of M2 macrophages and lower levels of plasma cells and CD8(+) T cells, and a reduced reaction rate for immunotherapy compared with low-risk group. After re-clustering CAFs via unsupervised clustering, we revealed 3 biologically distinct CAF subsets, namely myofibroblast-like CAFs (myCAFs), immune and inflammatory CAFs (iCAFs) and antigen-presenting CAFs (apCAFs). In conclusion, the CAF-derived signature, the first of its kind, can effectively predict PCa prognosis and serve as an indicator for immunotherapy. Furthermore, our study identified 3 CAF subpopulations with distinct functions in PCa.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] Integrative analyses of bulk and single-cell RNA-seq identified cancer-associated fibroblasts-related signature as a prognostic factor for immunotherapy in NSCLC
    Shasha Wang
    Guangyu Fan
    Lin Li
    Yajun He
    Ning Lou
    Tongji Xie
    Liyuan Dai
    Ruyun Gao
    Mengwei Yang
    Yuankai Shi
    Xiaohong Han
    Cancer Immunology, Immunotherapy, 2023, 72 : 2423 - 2442
  • [42] Integrative analyses of bulk and single-cell RNA-seq identified cancer-associated fibroblasts-related signature as a prognostic factor for immunotherapy in NSCLC
    Wang, Shasha
    Fan, Guangyu
    Li, Lin
    He, Yajun
    Lou, Ning
    Xie, Tongji
    Dai, Liyuan
    Gao, Ruyun
    Yang, Mengwei
    Shi, Yuankai
    Han, Xiaohong
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (07) : 2423 - 2442
  • [43] Cancer-Associated Fibroblast Heterogeneity, Activation and Function: Implications for Prostate Cancer
    Owen, Jasmine S.
    Clayton, Aled
    Pearson, Helen B.
    BIOMOLECULES, 2023, 13 (01)
  • [44] Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels the heterogeneity of cancer-associated fibroblasts in TNBC
    Wu, Xiaoqing
    Lu, Wenping
    Zhang, Weixuan
    Zhang, Dongni
    Mei, Heting
    Zhang, Mengfan
    Cui, Yongjia
    Zhuo, Zhili
    AGING-US, 2023, 15 (21): : 12674 - 12697
  • [45] Integrating single-cell and bulk RNA sequencing to predict prognosis and immunotherapy response in prostate cancer
    Wen, Xiao Yan
    Wang, Ru Yi
    Yu, Bei
    Yang, Yue
    Yang, Jin
    Zhang, Han Chao
    SCIENTIFIC REPORTS, 2023, 13 (01):
  • [46] Integrating single-cell and bulk RNA sequencing to predict prognosis and immunotherapy response in prostate cancer
    Xiao Yan Wen
    Ru Yi Wang
    Bei Yu
    Yue Yang
    Jin Yang
    Han Chao Zhang
    Scientific Reports, 13 (1)
  • [47] Single-cell RNA sequencing reveals heterogeneity in ovarian cancer and constructs a prognostic signature for prognostic prediction and immunotherapy (vol 140, 112855, 2024)
    Zhou, Shisi
    Li, Huiyan
    Zhao, Chengzhi
    Zhao, Wancheng
    Pan, Xue
    Jian, Weilan
    Wang, Jieli
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 143
  • [48] Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse
    Taavitsainen, S.
    Engedal, N.
    Cao, S.
    Handle, F.
    Erickson, A.
    Prekovic, S.
    Wetterskog, D.
    Tolonen, T.
    Vuorinen, E. M.
    Kiviaho, A.
    Natkin, R.
    Hakkinen, T.
    Devlies, W.
    Henttinen, S.
    Kaarijarvi, R.
    Lahnalampi, M.
    Kaljunen, H.
    Nowakowska, K.
    Syvala, H.
    Blauer, M.
    Cremaschi, P.
    Claessens, F.
    Visakorpi, T.
    Tammela, T. L. J.
    Murtola, T.
    Granberg, K. J.
    Lamb, A. D.
    Ketola, K.
    Mills, I. G.
    Attard, G.
    Wang, W.
    Nykter, M.
    Urbanucci, A.
    NATURE COMMUNICATIONS, 2021, 12 (01)
  • [49] Integration of Single-Cell and Bulk RNA-seq Data to Identify the Cancer-Associated Fibroblast Subtypes and Risk Model in Glioma
    Yan, Xiuwei
    Gao, Xin
    Dong, Jiawei
    Wang, Fang
    Jiang, Xiaoyan
    Hu, Xueyan
    Zhang, Jiheng
    Wang, Nan
    Xu, Lei
    Liu, Zhihui
    Hu, Shaoshan
    Zhao, Hongtao
    BIOCHEMICAL GENETICS, 2024, 63 (2) : 1275 - 1297
  • [50] Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse
    S. Taavitsainen
    N. Engedal
    S. Cao
    F. Handle
    A. Erickson
    S. Prekovic
    D. Wetterskog
    T. Tolonen
    E. M. Vuorinen
    A. Kiviaho
    R. Nätkin
    T. Häkkinen
    W. Devlies
    S. Henttinen
    R. Kaarijärvi
    M. Lahnalampi
    H. Kaljunen
    K. Nowakowska
    H. Syvälä
    M. Bläuer
    P. Cremaschi
    F. Claessens
    T. Visakorpi
    T. L. J. Tammela
    T. Murtola
    K. J. Granberg
    A. D. Lamb
    K. Ketola
    I. G. Mills
    G. Attard
    W. Wang
    M. Nykter
    A. Urbanucci
    Nature Communications, 12